Novel Biologics for Psoriasis

References1. Gordon K. Efficacy and safety of risankizumab: results from two double-blind, placebo- and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis. Presented at: 2018 American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA. Abstract 6495.2. Reich KDJ. Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: results from VOYAGE 2. Presented at: 2018 American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA. Abstract 6748.3. Papp KA. Dual neutralization of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe psoriasis: results from a phase 2b, randomized, double-blinded, placebo-controlled, dose-ranging study. Presented at: 2018 American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA. Abstract 6696.